A Study Of CG-806 In Patients With Relapsed Or Refractory CLL/SLL ...
Maybe your like
Tag » Apto-cg-806-01
-
A Study Of CG-806 In Patients With Relapsed Or Refractory AML Or ...
-
Aptose Doses First CLL Patient In Phase 1 Study Of CG-806 And ...
-
Luxeptinib For CLL & NHL - Aptose Biosciences Inc.
-
Aptose Presents New Preclinical Data On CG-806 And APTO-253
-
Aptose Presents Early Phase 1a/b CG-806 Clinical Findings
-
FDA Allows Human Trials Of Aptose's CG-806 Oral Compound For AML
-
CG'806, A First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits ...
-
Luxeptinib - Aptose Biosciences/CrystalGenomics - AdisInsight
-
CG-806 For Relapsed Or Refractory CLL/SLL Or Non-Hodgkin's ...
-
18281-Waldenström Macroglobulinemia-NA-596
-
A Study Of CG-806 In Patients With Relapsed Or Refractory CLL/SLL ...
-
BRIEF-Aptose Prioritizes Development Of CG'806 First-in Class FLT3 ...
-
Aptose Prioritizes Development Of CG'806 First-in Class FLT3/BTK ...